Ms. Roya Mohammadi Mey Abadi | Pharmacology | Best Researcher Award
Faculty of Pharmacy and Food Sciences at University of Barcelona, Spain
Roya Mohammadi Mey Abadi is a promising Ph.D. candidate at the University of Barcelona, specializing in biotechnology and nanobiotechnology. Her thesis focuses on the development of novel formulations of Baricitinib for psoriasis treatment, showcasing her commitment to addressing significant health challenges. With a robust educational background and extensive research experience, she has already contributed significantly to the field through various publications and conference presentations.
professional profile
Education 
Roya Mohammadi Mey Abadi holds a Ph.D. in Biotechnology-Nanobiotechnology from the University of Barcelona, where she is conducting research on innovative Baricitinib formulations for psoriasis treatment. She previously earned a Master of Science in Translational Medicine from the same institution, focusing on pharmacogenomics in obsessive-compulsive disorder. Her early academic journey includes another Master’s degree in Biology/Zoology, specializing in Evolutionary Cellular Biology from Parand Islamic Azad University, where she studied the effects of hydroalcoholic extracts on spermatogenesis in mice. Additionally, she holds a Bachelor’s degree in Plant Biology from Damghan Islamic Azad University. This extensive education has equipped Roya with a strong foundation in both biological sciences and advanced research methodologies, enabling her to contribute effectively to the fields of biotechnology and pharmaceuticals.
work Experience
Roya Mohammadi Mey Abadi has gained significant research experience throughout her academic career. She undertook an apprenticeship in practical molecular biology and genetics at the Medical Genetics Laboratory in Tehran, where she acquired hands-on skills in molecular testing techniques. Most recently, she completed an internship at the National Institute of Genetics and Biotechnology in Tehran, focusing on the identification of new genes in the Iranian population. Her research experience includes extensive work on Baricitinib, leading to various publications and presentations at international conferences. Through her roles, she has developed expertise in pharmaceutical calculations, drug delivery systems, and biopharmaceutical studies for transdermal delivery. Roya is also proficient in several analytical techniques such as HPLC, UV-Vis spectroscopy, and fluorescence spectroscopy. Her work with laboratory animal models further enhances her practical skills, making her a well-rounded researcher in biotechnology.
Research Focus
Roya Mohammadi Mey Abadi’s research focuses primarily on biotechnology and nanobiotechnology, with a particular emphasis on drug delivery systems for dermatological treatments. Her Ph.D. thesis centers on developing and evaluating novel Baricitinib formulations aimed at treating psoriasis, an inflammatory skin condition. By exploring the pharmacokinetics and biopharmaceutical properties of Baricitinib, she aims to enhance its therapeutic efficacy through innovative delivery methods, including liposomes and microemulsions. Her previous research has also involved pharmacogenomics, investigating genetic factors associated with obsessive-compulsive disorder. Throughout her academic journey, Roya has demonstrated a commitment to addressing significant health challenges through her research. She actively participates in international conferences to share her findings, engage with peers, and contribute to advancements in the field of pharmaceuticals. Roya’s goal is to translate her research into practical applications that improve patient care and treatment outcomes in dermatology and beyond.
Awards and honors
Roya Mohammadi Mey Abadi has received recognition for her outstanding contributions to research and innovation. She was awarded the 1st Prize for “Best Pitch” during the ‘From Lab to Market’ workshop series in Nucleate Spain in May 2024, highlighting her entrepreneurial spirit and ability to translate scientific research into marketable solutions. Additionally, her participation in various prestigious conferences, such as the SKIN FORUM and ECFA International Meeting, has allowed her to showcase her research findings and engage with leading experts in the field. Her work on Baricitinib has been featured in multiple international journals, contributing to her growing reputation in pharmaceutical sciences. Through these achievements, Roya has established herself as a promising researcher, garnering attention for her innovative approaches to drug delivery and skin treatment solutions, ultimately positioning her as a future leader in biotechnology.
Conclusion
Roya Mohammadi Mey Abadi stands out as a strong candidate for the Best Researcher Award. Her academic achievements, research contributions, and communication skills position her well to make a significant impact in the field of pharmaceutical sciences. By continuing to develop her research scope and collaborating with others, she has the potential to become a leader in educational research, driving innovations that could benefit healthcare outcomes globally. Awarding her this recognition would not only validate her hard work but also inspire her to continue pushing the boundaries of research in biotechnology.
Publications to Noted
Title: Formulation of Polymeric Nanoparticles Loading Baricitinib as a Topical Approach in Ocular Application
Authors: Roya Mohammadi Mey Abadi, S. I. Ahmadi, M. T. Zohari
Citations: Not available yet (recent publication)
Year: 2024
DOI: 10.3390/pharmaceutics16081092
Source: Pharmaceutics
Title: Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies
Authors: Roya Mohammadi Mey Abadi, M. Zohari, S. I. Ahmadi
Citations: 2 (as of now)
Year: 2022
DOI: 10.3390/pharmaceutics14122714
Source: Pharmaceutics
Title: Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome
Authors: Roya Mohammadi Mey Abadi, M. Zohari, S. I. Ahmadi
Citations: 5 (as of now)
Year: 2022
DOI: 10.3390/pharmaceutics14091895
Source: Pharmaceutics